Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial-Reference-Cited by-同舟云学术

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

Published:2011-01 Issue:1 Volume:10 Page:54-61
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Konstan Michael W.,Flume Patrick A.,Kappler Matthias,Chiron Raphaël,Higgins Mark,Brockhaus Florian,Zhang Jie,Angyalosi Gerhild,He Ellie,Geller David E.

Funder

Novartis Pharma AG

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference25 articles.

1. Pathophysiology and management of pulmonary infections in cystic fibrosis;Gibson;Am J Repir Crit Care Med,2003

2. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis;Henry;Pediatr Pulmonol,1992

3. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis;Ballmann;Thorax,1998

4. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition;Kosorok;Pediatr Pulmonol,2001

5. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis;Emerson;Pediatr Pulmonol,2002

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations Affecting Cellular Levels of Cobalamin (Vitamin B₁₂) Confer Tolerance to Bactericidal Antibiotics in Burkholderia cenocepacia;Journal of Microbiology and Biotechnology;2024-07-11

2. S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa;Pneumologie;2024-02-13

3. The quest to deliver high-dose rifampicin: can the inhaled approach help?;Expert Opinion on Drug Delivery;2024-01-02

4. Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection;BMC Microbiology;2023-10-27

5. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective;The Lancet Respiratory Medicine;2023-10